Alexion Pharmaceuticals, Inc. today announced the presentation of two-year data that highlight the long-term benefits of chronic Soliris® therapy in patients with atypical hemolytic uremic syndrome , an ultra-rare genetic disease characterized by thrombotic microangiopathy , the formation of blood clots in small blood vessels throughout the body.
